Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Migrant legal STATUS diversity and diversity dynamics in European CITIES (StatusCities)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Netherlands
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2017-09-01
End date: 2019-08-31
Duration (months): 24.0
Total project cost (EUR): 165598.8
EU funding (EUR): 165598.8
Participants: 1
Project status: CLOSED

StatusCities will provide a comprehensive investigation of the city level implications of migrants being differentiated by a myriad of legal status tracks. Conceptually and empirically focussing on superdiversity and diversity dynamics – rather than cross-sectional configurations - the specific aim is to link debates about the national level management of migration with debates on urban migration-related diversities. This is extremely timely given unprecedented migration to Europe and especially to Europe's cities. Asking where migrants subject to different legal status conditions live and what their residential biographies look like, StatusCities will combine an analysis of both unique longitudinal register data and qualitative data derived through mobile-phone supported long term elicitation techniques. The former will be used to map and visualise migrant residential patterns in light of status differentiations, the latter to analyse city and neighbourhood level patterns by paying attention to individual mobility and sociality decisions at the time of legal status transitions. The project will be focused on four urban centres located in one of Europe’s major conurbations the Dutch Randstad. The research will consider multiple scales of analysis through a focus on different types and differently sized cities and within them neighbourhoods that show a relatively high turnover of different status migrants. StatusCities will thus contribute knowledge and methodological innovation by drawing on debates from various disciplinary fields and using a sophisticated and innovative mixed methods approach. Research has not yet investigated how the multiplicity of status differences - with their associated eligibility criteria and the parameters of presence that they set out - are relevant to dynamic changes in migration-related diversity. With the current levels of migration StatusCities is devoted to filling this highly policy relevant knowledge void.

Keywords: superdiversity,urban diversity,migrant legal statuses
Automation of novel multi-parameter allergy test that is cost-efficient and delivers instantly correct results (AllergyExplorer)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Austria
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2018)
Start date: 2018-06-01
End date: 2020-05-31
Duration (months): 24.0
Total project cost (EUR): 3536250.0
EU funding (EUR): 2475375.0
Participants: 1
Project status: CLOSED

Allergies and asthma affect at least a quarter of the population and the WHO has declared allergy a major health problem of the 21st century. Currently, medical practitioners must pre-select very few allergens for in-vitro testing, based on prior anamnesis, under time and cost pressure. Independent experts estimate that almost half of the patients are diagnosed insufficiently. The consequences for the patients are not optimal treatment and reduced quality of life. For the public health systems more than 140 Bn Euro are spent each year which could be saved if all allergic patients were treated adequately. We have developed a multi-parameter allergy test covering close to 100% of the globally relevant allergens in a single lab test. Instead of forcing medical practitioners to pre-select very few allergens for in-vitro, our solution substantiates any therapeutic decision by offering a complete immunological profile for every tested individual. We expand testing to the molecular level which provides valuable decision points such as enhanced risk assessment, improving the success of allergen immunotherapy or clearer recommendations for avoidance. We eliminate the trade-off between cost and quality of allergy diagnosis. Our allergy test is technically validated and registered as an in-vitro diagnostics device in Europe. We are already selling and delivering the non-automated manual test systems to customers all over Europe. In this project, we will fully automate the test instrumentation so we can target the customer segments of highly automated clinical routine labs. This will multiply our selling potential and expand our customer reach. The global market of in-vitro diagnosis of allergy is growing fast at almost double-digit rate globally, and amounted to approx. 700 million USD annual revenues in 2016. There is a de-facto monopoly of a single US supplier and this project will return jobs and revenues to the European Union.

Keywords: allergy test,in vitro diagnosis,multi parameter immunoassay,allergen
Comet and Asteroid Re-Shaping through Activity (CAstRA)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Universe sciences
Panel description: Astro-physics/-chemistry/-biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: Germany,Germany
Call: ERC Starting Grant (ERC-2017-STG, 2017)
Start date: 2018-03-01
End date: 2023-08-31
Duration (months): 66.0
Total project cost (EUR): 1484688.0
EU funding (EUR): 597534.61
Participants: 2
Project status: SIGNED

The proposed project will significantly improve the insight in the processes that have changed a comet nucleus or asteroid since their formation. These processes typically go along with activity, the observable release of gas and/or dust. Understanding the evolutionary processes of comets and asteroids will allow us to answer the crucial question which aspects of these present-day bodies still provide essential clues to their formation in the protoplanetary disc of the early solar system. Ground-breaking progress in understanding these fundamental questions can now be made thanks to the huge and unprecedented data set returned between 2014 and 2016 by the European Space Agency’s Rosetta mission to comet 67P/Churyumov-Gerasimenko, and by recent major advances in the observational study of active asteroids facilitated by the increased availability of sky surveys and follow-on observations with world-class telescopes. The key aims of this proposal are to - obtain a unified quantitative picture of the different erosion processes active in comets and asteroids, - investigate how ice is stored in comets and asteroids, - characterize the ejected dust (size distribution, optical and thermal properties) and relate it to dust around other stars, - understand in which respects comet 67P can be considered as representative of a wider sample of comets or even asteroids. We will follow a highly multi-disciplinary approach analyzing data from many Rosetta instruments, ground- and space-based telescopes, and connect these through numerical models of the dust dynamics and thermal properties.

Keywords: comet activity,active asteroids,cometary dust,rosetta mission
Manufacturing and testing of an allogeneic gamma delta T cell therapy for the treatment of cancer (OmnImmune)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: United Kingdom
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-2-2016-2017, 2017)
Start date: 2017-10-01
End date: 2019-09-30
Duration (months): 24.0
Total project cost (EUR): 3957000.0
EU funding (EUR): 3957000.0
Participants: 1
Project status: CLOSED

Europe is experiencing an unprecedented cancer epidemic, driven by our ageing population. Traditional cancer treatments such as surgery, chemotherapy and radiation therapy have demonstrated very limited efficacy for patients with late-stage disease and often cause considerable side effects. Cell therapies are the next breakthrough in oncology, but autologous cells must be harvested from each patient, expanded for several weeks in vitro and re-administered to the same patient while hospitalized. TCB, a Scottish SME, brings the first allogeneic gamma delta T cell therapy (OmnImmune) where T cells harvested from healthy donors are used to treat multiple recipients. OmnImmune represents a truly disruptive, step-changing approach to the treatment of a wide variety of cancers. It has the potential to be manufactured for large market segments at a lower cost than competitors and provide valuable increases to the quality of life of life. OmnImmune will provide next generation cancer treatment at 20% of the cost of any other cell therapy, saving €24Bn per year for 60,000 patients treated. OmnImmune’s unique characteristics make it a truly disruptive treatment solution for patients and clinicians: Multifunctional treatment solution: available to all cancer patients, regardless of their disease grade or immune status Predicted high safety profile: minimal side-effects based on clinical data from trials of autologous GDT cells (to be confirmed in dose-escalation clinical trial) Ease of use and lower cost: frozen dose-ready units available for immediate patient administration. The SME Instrument funding will accelerate the development of the OmnImmune therapy and reduce its time to market from 10 years to 6 years. This will allow OmnImmune to reach the market by 2024.

Keywords: allogeneic cell therapy,gamma delta t cells
KWatch Glucose: A Wearable Painless Continuous Glucose Monitoring Smartwatch (K Watch Glucose)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2020-11-01
End date: 2023-10-31
Duration (months): 36.0
Total project cost (EUR): 3271376.25
EU funding (EUR): 2289963.38
Participants: 1
Project status: SIGNED

Most diabetes preventable emergencies, like severe hypoglycaemia (cost of €1535.8/event in Europe), are linked to a poor self- management. Diabetes management relies on blood glucose (BG) monitoring several times a day. Only 20% of the 100M people that should monitor their glucose does it periodically and correctly. This is caused, partially, by the inconveniences of available self-monitoring devices: these devices are painful, burdensome, and expensive. We have developed K'Watch Glucose, a minimally invasive glucose self-monitoring system embedded in a smartwatch. Our innovative technology measures glucose levels from extracted interstitial fluid (ISF), without painful blood-sampling and high accuracy (99%). This is possible thanks to SkinTaste®, a patented, calibration-free biosensor array that uses micro-needles (<0.7mm long) to collect and analyze chemical composition of the interstitial fluid. Thanks to its small size, our solution stays “invisible” to others, enabling monitoring of glucose levels anytime and anywhere, without anyone noticing. In the Accelerator, we will prepare K’Watch Glucose for its successful launch in the European Union and in North America by validating it clinically in our target markets, certifying it as a Class 2 medical device, by pursuing its industrialisation, preparing its reimbursement and establishing a solid commercial network of distributors, insurances and users. K’Watch Glucose could have a significant impact on preventing avoidable hypoglycaemia episode and its associated complications. Considering that we expect to have 830k active users by the end on our 5th commercialization year, K’Watch Glucose could potentially save around €1.27M per year in Europe and $0.96M in US derived just from preventing severe complications led by hypoglycaemia. In 5 years from the Accelerator Program, we estimate a cumulative Profit of €201.1M with a ROI of 10.53, besides a clear social benefit with the recruitment of 139 new employees.

Keywords: diabetes,glucose monitoring,hypoglycemia prevention,wearable
People, Place, Policy and Practice for Play (P4PLAY)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Joint Doctorates
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Ireland,Switzerland,Sweden,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2019, 2019)
Start date: 2020-03-01
End date: 2024-06-30
Duration (months): 52.0
Total project cost (EUR): 2275640.64
EU funding (EUR): 2275640.64
Participants: 4
Project status: SIGNED

Conformity with the call and work programme: There is a significant shortage of researchers in Occupational Science and Occupational Therapy in Europe. Only five European countries offer PhDs in Occupational Therapy, while none offer PhDs in Occupational Science, which severely restricts professional education and practice and ultimately impacts patients, and families, who receive occupational therapy services. Therefore, the societal challenge for improving health professions training and knowledge in evidence-based practice is a priority for the profession. This European Joint Doctorates programme responds to this challenge in Occupational Therapy career development across Europe through the study of play from an occupational science perspective. The overall research goal is to develop new knowledge on the occupation of play and play deprivation, the impact of physical, socio-cultural, and policy environments on play provision, and the development of innovative solutions to address barriers and provide solutions to play provision in diverse community settings to benefit children, families, and communities. The P4Play programme address four areas of play: play occupation, policy, places and practice. The EJD will establish the first innovative trans-European Occupational Therapy doctoral training programme dedicated to play occupation, participation, policy and practice. The fundamental aim is to develop a sustainable doctoral programme that delivers ambitious and high-quality graduates to drive innovative research and practice in occupational science and therapy. Increasing occupational therapist’s ability to be consumers and producers of research is vital to transform therapy practice so that it is research-informed and evidence-based. The overall goal is to build the capacity of therapists to develop creative solutions towards social transformation.

Keywords: socio spatial inclusion,play,children,families,communities
Identification and characterization of bacterial effectors that interfere with Transcriptional Gene Silencing in Arabidopsis (BASILA)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-11-16
End date: 2017-11-15
Duration (months): 24.0
Total project cost (EUR): 173076.0
EU funding (EUR): 173076.0
Participants: 1
Project status: CLOSED

Transcriptional gene silencing (TGS) is an ancestral gene regulatory mechanism that operates at the level of chromatin and that involves various histone modifications as well as cytosine DNA methylation. In both plants and animals, DNA methylation transcriptionally silences transposable elements (TEs), repeats, as well as some protein-coding genes that carry TEs/repeats in their vicinity. Whereas DNA methylation has been extensively studied at particular stages of plants and animals development, its dynamics and biological relevance in response to biotic stresses, and particularly during bacterial infections, has just started to be examined and reported. Previous work from the host laboratory has revealed that disease-related genes are negatively regulated by DNA methylation and that DNA demethylation is required to enable proper plant innate immune response. Together, these results suggest that some yet-unknown bacterial virulence factors must have evolved to interfere with TGS to enable disease. The proposed project aims at identifying and characterizing such bacterial effectors as well as their interactants, namely epigenetic factors. To address these questions, the bacterial pathogen Pseudomonas syringae and the plant Arabidopsis thaliana will be used as model systems and biochemical, genetic, epigenomic and cell biology approaches combined. The proposed project sets the grounds for further mechanistic analyses of the effector-target complexes that will shed light on the precise mode of action of these epigenetic effectors and their targets. This study will not only unveil novel mechanisms of bacterial pathogenicity but also allow the identification of novel silencing factors and therefore enhance our fundamental knowledge of TGS mechanisms in plants and possibly other eukaryotic organisms.

Keywords: epigenetics,bacterial effectors,dna methylation,rna silencing,mamp
Improved Patient Care by Combinatorial Treatment (IMPACCT)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Spain
Call: ERC Proof of Concept Grant (ERC-2018-PoC, 2018)
Start date: 2019-01-01
End date: 2020-12-31
Duration (months): 24.0
Total project cost (EUR): 145000.0
EU funding (EUR): 145000.0
Participants: 1
Project status: CLOSED

Targeted precision medicine combined with companion diagnostics will provide the basis for future more effective more economic patient care. Recent advances in breast cancer treatment combining inhibitors of poly-ADP-ribose polymerase (PARP1) in conjunction with other targets are at the forefront of this new advance both at the level of basic research and pharmaceutical interest, due to its pivotal role in gene expression, chromatin and repair. We have discovered a key enzyme downstream of PARP1 which generates ATP locally in the nucleus; NUDIX5. This enzyme is overexpressed in cancer and correlates with poor prognosis, as the activity of this enzyme is essential for changes within the 3D chromatin structure, gene regulation and the proliferation of cancer cells. We have developed inhibitors of NUDIX5 in addition to a companion diagnostic, and propose to prove using a multi-disciplinary, international collaborative effort that they can be used to determine not only patient risk and treatment options but also provide an exciting new avenue for the combinatorial treatment of breast and (we hope) other cancer patients.

Keywords: cancer biomarker,precision medicine,genomics,3d chromatin structure,multi disciplinary,systems biology,structural biology,molecular biology,lead compound validation,companion diagnostic,syg6 synergy panel 6
An Etymological Dictionary of the Japonic Languages (EDJ)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Cultures and cultural production
Panel description: Literary studies, cultural studies, study of the arts, philosophy
Countries involved: Poland,New Zealand,France,Japan
Call: ERC Advanced Grant (ERC-2017-ADG, 2017)
Start date: 2019-01-01
End date: 2025-06-30
Duration (months): 78.0
Total project cost (EUR): 2470200.0
EU funding (EUR): 1898950.0
Participants: 4
Project status: CLOSED

It is a paradoxical situation that with Japan being the third modern economy and Japanese, the main Japonic language, being the 10th in the world in terms of native speakers and the most widely studied Asian language, the Japonic language family still lacks an etymological dictionary. The present research project will rectify this situation. The benefits of an etymological dictionary of Japonic are obvious: not only it will be of a great use to the specialists working on pre-modern Japan and Ryukyuan islands in various disciplines; it will have its impact on modern studies, especially on linguistic identities in East Asia. And offer a new reading of regional linguistic identities The Etymological Dictionary of the Japonic languages has never been compiled, and the time for the realization of such a project is ripe, as it would have been impossible to carry on 30 or 40 years ago, since many important resources available now did not yet exist then such as numerous dictionaries and descriptions of dialects and historical stages of the language development. The same is true regarding the editions of many textual sources and compilation of their indexes. One very important difference with the previous era is also the fact that nowadays many sources are available electronically, which greatly facilitates the search and management of information. This project is highly innovative because it provides a presentation in context based on the extensive use of the IT technology, as compared to the previous research on Japonic etymology which was essentially word-list-oriented. In contrast with the current practice, where only word entries with their translations were provided (and often without any reference to the source), thanks to internet link to database, and cross-referenced entries, the electronic etymological dictionary will present the words in their textual historical and cultural context.

Keywords: etymology,japonic,japanese,ryukyuan,ainu,middle and old korean,middle and old,chinese,comparative method